Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 2024
DOI: 10.1177/08968608241231697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2024. Verfasst von Zhong Zhong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factor-23, Fibroblast Growth Factors, Kidney Failure, Chronic, Peritoneal Dialysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone that is secreted in large amounts early in chronic kidney disease. In this cohort, we aimed to investigate the association between serum FGF23 concentration and mortality in patients undergoing peritoneal dialysis (PD).
Methods
Serum FGF23 level was determined by enzyme-linked immunosorbent assay (ELISA) in a large 15-year prospective cohort study of PD patients with stored serum samples at baseline. Kaplan–Meier survival curves and Cox proportional hazards models were performed to characterise the relationship of FGF23 with mortality.
Results
A total of 737 incident PD patients were analysed. The baseline median FGF23 concentration was 683.2 (518.5–896.2) pg/mL. Age, serum phosphorus, high-density lipoprotein cholesterol and high-sensitivity C-reactive protein were independently correlated with serum FGF23 concentration. During a median follow-up of 66.7 (41.1–95.4) months, 171 of the 737 participants (23.2%) died, including 84 (49.1%) cardiovascular disease-related and 50 (29.2%) infection-related deaths. Multivariable Cox regression analysis showed that the adjusted hazard ratios of the highest tertile of serum FGF23 compared with those in the lowest tertile were 1.36 (95% confidence interval (CI): 0.89–2.07; p = 0.154), 0.75 (95% CI: 0.40–1.38; p = 0.353) and 2.66 (95% CI: 1.15–6.15; p = 0.022) for all-cause, cardiovascular disease-related and infection-related mortality, respectively.
Conclusion
High serum FGF23 concentration is associated with a higher risk of infection-related death for incident PD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- NHC Key Laboratory of Clinical Nephrology (Sun Yat-sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.
- Zhong Zhong and Shaozhen Feng contributed equally to this manuscript.
- Clinical Trials Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Zhong Zhong
Zitieren
APA
Zhong, Z., Feng, S., Fu, D., Li, B., Li, Z., & Mao, H. (2024). Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608241231697
Vancouver
Zhong Z, Feng S, Fu D, Li B, Li Z, Mao H. Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2024. doi:10.1177/08968608241231697
BibTeX
@article{Zhong2024,
author = {Zhong, Zhong and Feng, Shaozhen and Fu, Dongying and Li, Bin and Li, Zhijian and Mao, Haiping},
title = {Serum fibroblast growth factor 23 concentration and the risk of mortality in patients undergoing peritoneal dialysis},
journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
year = {2024},
doi = {10.1177/08968608241231697}
}
EUVIMED